Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ASTX030

Phase 1Small molecule

Taiho Oncology, Inc.

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myelodysplastic Syndrome (MDS)Recruiting

Myelodysplastic Syndrome (MDS)Phase 1

Recruiting

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Myelodysplastic Syndrome (MDS)

NCT04608110

Q4 2028

PreclinicalRecruiting

Myelodysplastic Syndromes

NCT04256317

Clinical

Trials by Indication[1]

Myelodysplastic Syndromes1 trial

A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects With Myeloid Neoplasm or in Combination With Venetoclax in Subjects With AML (AZTOUND Study)

Recruiting· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Preclinical·NCT04256317·316 enrolled

Myelodysplastic Syndrome (MDS)1 trial

A Phase 1, Multi-center, Open-label, Uncontrolled, Dose-escalation Study to Evaluate the Pharmacokinetics of ASTX030 in Patients With Myelodysplastic Syndrome (MDS)

Recruiting· Taiho Pharmaceutical Co., Ltd. logo

Taiho Pharmaceutical Co., Ltd.·Phase 1·NCT04608110·59 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ASTX030. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ASTX030 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ASTX030. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Taiho Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Taiho Oncology, Inc.

Related News